Adnectin, a VEGFR2 inhibitor, in combination with AT580Peg40, an IGF-1R inhibitor, reduced tumor growth by 83.4% in mice by normalizing the microvascular architecture via inhibition of autocrine VEGF-secretion and downregulation of IGF-1R. Here, KDR is linked to neoplasm.